- /
- Supported exchanges
- / US
- / LTGO.NASDAQ
Latigo Biotherapeutics, Inc. Common Stock (LTGO NASDAQ) stock market data APIs
Latigo Biotherapeutics, Inc. Common Stock Financial Data Overview
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Latigo Biotherapeutics, Inc. Common Stock data using free add-ons & libraries
Get Latigo Biotherapeutics, Inc. Common Stock Fundamental Data
Latigo Biotherapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -112 164 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Latigo Biotherapeutics, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-09-03
- EPS/Forecast: -0.66
Get Latigo Biotherapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Latigo Biotherapeutics, Inc. Common Stock News
New
The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’
The past several years saw muted IPO activity, a generally negative signal for market health. But 2026 has reversed that trend. Yes, you can say that the June IPO of SpaceX, the largest ever public of...
Inside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes Public
Quick Read LTGO priced its IPO at $18, opened at $21, and raised nearly $350 million from an oversubscribed offering. LTG-001 delivered 50% greater pain relief than hydrocodone in a 343-patient trial...
Non-Opioid Painkiller Maker Latigo Jumps 17% After Upsized IPO
(Bloomberg) -- Latigo Biotherapeutics Inc., a clinical-stage developer of non-opioid pain medicines, climbed 17% on Friday after raising $345.6 million in an upsized initial public offering, priced at...
Latigo IPO raises nearly $350M for pain drug development
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Pain drugmaker Latigo Biotherapeutics went public Thu...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.